Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dawson, L. J.
Right arrow Articles by Field, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dawson, L. J.
Right arrow Articles by Field, E. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2000; 39: 234-237
© 2000 British Society for Rheumatology

Editorials

Sjögren's syndrome—time for a new approach

L. J. Dawson, P. M. Smith, R. J. Moots and E. A. Field

Rheumatology Research Group, The University of Liverpool, Department of Medicine, 3rd Floor UCD Building, Liverpool L69 3GA, UK

Sjögren's syndrome is one of a number of organ-specific, autoimmune diseases, which include rheumatoid arthritis. The classification of Sjögren's syndrome into primary and secondary forms has now been widely accepted, but the debilitating effects of xerostomia and xeropthalmia may go unrecognized for long periods of time despite a gradual increase in symptoms. The clinical consequences of Sjögren's syndrome range from difficulty in speaking and eating, oral candidosis, and rampant caries to chronic sialadenitis, blindness and B-cell lymphoma [1, 2]. Treatment of the disease, at the present time, is palliative and mainly restricted to ameliorating the effects of a dry mouth and dry eyes [3]. Data from epidemiological studies suggest that the prevalence of Sjögren's syndrome may approach, or even exceed [4], that of rheumatoid arthritis, which affects between 1 and 3% of the general population [5].

Research into Sjögren's syndrome has been limited . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
L. J. Dawson, P. C. Fox, and P. M. Smith
Sjogrens syndrome--the non-apoptotic model of glandular hypofunction
Rheumatology, July 1, 2006; 45(7): 792 - 798.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
L. J. Dawson, H. E. Allison, J. Stanbury, D. Fitzgerald, and P. M. Smith
Putative anti-muscarinic antibodies cannot be detected in patients with primary Sjogren's syndrome using conventional immunological approaches
Rheumatology, December 1, 2004; 43(12): 1488 - 1495.
[Abstract] [Full Text] [PDF]